Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-Outcomes of a randomized trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10210258" target="_blank" >RIV/00216208:11110/13:10210258 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.drugalcdep.2013.06.024" target="_blank" >http://dx.doi.org/10.1016/j.drugalcdep.2013.06.024</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.drugalcdep.2013.06.024" target="_blank" >10.1016/j.drugalcdep.2013.06.024</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-Outcomes of a randomized trial

Popis výsledku v původním jazyce

Aims: Determine the extent to which buprenorphine injectors continue treatment with buprenorphinenaloxone or methadone, and the impact of these treatments on substance use and HIV risk in the Republic of Georgia. Methods: Randomized controlled 12-week trial of daily-observed methadone or buprenorphine-naloxone followed by a dose taper, referral to ongoing treatment, and follow-up at week 20 at the Uranti Clinic in Tbilisi, Republic of Georgia. Eighty consenting treatment-seeking individuals (40/group) aged 25 and above who met ICD-10 criteria for opioid dependence with physiologic features and reported injecting buprenorphine 10 or more times in the past 30 days. Opioid use according to urine tests and self-reports, treatment retention, and HIV risk behavior as determined by the Risk Assessment Battery. Results: Mean age of participants was 33.7 (SD5.7), 4 were female, mean history of opioid injection use was 5.8 years (SD4.6), none were HIV+ at intake or at the 12-week assessment and

Název v anglickém jazyce

Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-Outcomes of a randomized trial

Popis výsledku anglicky

Aims: Determine the extent to which buprenorphine injectors continue treatment with buprenorphinenaloxone or methadone, and the impact of these treatments on substance use and HIV risk in the Republic of Georgia. Methods: Randomized controlled 12-week trial of daily-observed methadone or buprenorphine-naloxone followed by a dose taper, referral to ongoing treatment, and follow-up at week 20 at the Uranti Clinic in Tbilisi, Republic of Georgia. Eighty consenting treatment-seeking individuals (40/group) aged 25 and above who met ICD-10 criteria for opioid dependence with physiologic features and reported injecting buprenorphine 10 or more times in the past 30 days. Opioid use according to urine tests and self-reports, treatment retention, and HIV risk behavior as determined by the Risk Assessment Battery. Results: Mean age of participants was 33.7 (SD5.7), 4 were female, mean history of opioid injection use was 5.8 years (SD4.6), none were HIV+ at intake or at the 12-week assessment and

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Drug and Alcohol Dependence

ISSN

0376-8716

e-ISSN

—

Svazek periodika

133

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

7

Strana od-do

376-382

Kód UT WoS článku

000328240900011

EID výsledku v databázi Scopus

—